Richard Leigh is a Neurology physician. ClinicalTrials.gov lists 12 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Research metrics aren't shown for this record. Either we found no confident publication match for this name, or more than one physician shares the matched author record. We'd rather show nothing than someone else's numbers. Why? →
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
600 N Wolfe St
Baltimore, MD 212870005
Telephone
410-614-2381Registry record last updated 2 Feb 2011.
Clinical trials
- Path Active Multicentre Randomised Controlled Trial (Previous Pilot: Path Active; Safety and Tolerability Study)
Sponsor: Royal Free Hospital NHS Foundation Trust
- Imaging the Pathogenesis of Cerebral Small Vessel Disease
Sponsor: Johns Hopkins University
- Global Blood-Brain Barrier Disruption and Post-Stroke Cognitive Decline
Sponsor: Johns Hopkins University
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Nervous system
57.8%N-methyl-D-aspartate Receptor Antagonist33.3%Memantine Hcl100%Part D<11 patientsGabapentinoids24.4%Gabapentin100%Part D<11 patientsBlood & clotting
42.2%P2Y12 inhibitor42.2%Clopidogrel100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
1 NIH research award on record, funded 2022–2025 per NIH RePORTER. The latest:
- Global Blood-Brain Barrier Disruption and Post-Stroke Cognitive Decline
Johns Hopkins University
FY2025$598,564R01NS123386 - Global Blood-Brain Barrier Disruption and Post-Stroke Cognitive Decline
Johns Hopkins University
FY2024$621,691R01NS123386 - Global Blood-Brain Barrier Disruption and Post-Stroke Cognitive Decline
Johns Hopkins University
FY2023$620,597R01NS123386
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Similar KOLs
Other experts from the same institution or the same specialty.
Atte Meretoja
University of Helsinki
Bruce Miller, MD
University of California, San Francisco (UCSF)
Dennis Selkoe, MD
Brigham and Women's Hospital
Ettore Beghi
Mario Negri Institute for Pharmacological Research
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”